Ambulanzpartner Soziotechnologie APST GmbH
Industry / private company
Location:
Berlin,
Germany (DE)
Effects of tofersen treatment in patients with SOD1-ALS in a “real-world” setting – a 12-month multicenter cohort study from the German early access program (2024)
Wiesenfarth M, Dorst J, Brenner D, Elmas Z, Parlak Ö, Uzelac Z, Kandler K, et al.
Journal article
Clinical and patient-reported outcomes and neurofilament response during tofersen treatment in SOD1-related ALS—A multicenter observational study over 18 months (2024)
Meyer T, Schumann P, Weydt P, Petri S, Weishaupt JH, Weyen U, Koch JC, et al.
Journal article
Clinical characterization of common pathogenic variants of SOD1-ALS in Germany (2024)
Wiesenfarth M, Forouhideh-Wiesenfarth Y, Elmas Z, Parlak Ö, Weiland U, Herrmann C, Schuster J, et al.
Journal article